Developer docs
API playgroundTry for free, no card

Search company profiles

Enanta Pharmaceuticals

Full company profile

uuid0000cql

Namestring
Enanta Pharmaceuticals
Legal namestring
Enanta Pharmaceuticals, Inc.
Websiteurl
enanta.com
Company typeenum
Public
Founded yearint
1995
Descriptiontext

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunological diseases. Founded in 1995 and headquartered in Watertown, Massachusetts, the company operates with fewer than 200 employees and trades on NASDAQ under ticker ENTA. Enanta's research is anchored in medicinal chemistry and has historically focused on protease inhibitors, exemplified by the discovery of glecaprevir and paritaprevir — compounds commercialized by AbbVie in the HCV regimens MAVYRET/MAVIRET and VIEKIRA PAK, which have collectively cured more than one million patients.

The company's clinical pipeline spans multiple mechanisms of action: RSV antivirals (zelicapavir, an N-protein inhibitor advancing to registrational Phase 2b/3; and EDP-323, an L-protein inhibitor with Phase 2a data), a COVID-19 candidate (EDP-235, a 3CL protease inhibitor), an HBV core inhibitor (EDP-514), and an expanding immunology franchise (EDP-978, an oral KIT inhibitor in Phase 1; EPS-3903, a STAT6 inhibitor in IND-enabling studies; and MRGPRX2 inhibitors in discovery). Four candidates hold FDA Fast Track designation, supporting expedited development pathways.

Enanta's business model is dual-track. Revenue is generated almost entirely through royalty payments from AbbVie on worldwide sales of MAVYRET/MAVIRET — approximately $18.6 million in Q1 FY2026 — providing a cash-generative base that has historically delivered over $1 billion in non-dilutive financing through the AbbVie collaboration. The company is advancing pipeline assets toward registrational milestones with the intent of securing new commercialization partnerships or building independent sales capability for future launches. An October 2025 upsized public offering raised $74.75 million, extending the cash position to $241.9 million as of December 31, 2025 and funding operations into fiscal 2029. The company also retains optionality on pipeline assets via a dedicated business development function and historical collaborations with Novartis, Shionogi, and government funders.

Short descriptiontext

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunology, generating royalty revenue from AbbVie's hepatitis C treatments while advancing a pipeline in RSV, HBV, and inflammatory diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule drug discovery, antiviral therapeutics, hepatitis C treatment, RSV drug development, immunology drug development
Industry4 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Royalty Payments from AbbVie
TypeLicensing Royalties
Description

Enanta receives ongoing royalty payments from AbbVie based on sales of MAVYRET/MAVIRET (glecaprevir/pibrentasvir) for hepatitis C treatment. Revenue was $18.6 million in fiscal Q1 2026 (quarter ended December 31, 2025), up from $17.0 million in the prior year period.

biospace.com
2Public Stock Offering
TypeOne Time License
Description

Enanta raised approximately $74.75 million through an upsized public offering of 7,475,000 shares of common stock at $10.00 per share in October 2025 to fund clinical trials, research, and development, and general corporate purposes.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers, develops, and commercializes small molecule drugs for viral infections (HCV, RSV, HBV, COVID-19) and immunological diseases. Its marketed products (glecaprevir and paritaprevir, used in AbbVie's MAVYRET/MAVIRET and VIEKIRA PAK regimens for hepatitis C) are commercialized by AbbVie under a longstanding collaboration that has cured over one million patients. The company's clinical pipeline includes zelicapavir and EDP-323 for RSV, EDP-235 for COVID-19, EDP-514 for HBV, and EDP-978, EPS-3903, and MRGPRX2 inhibitors for immunology indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 96.2% sustained virological response rate at 12 weeks (SVR12) for MAVIRET in acute HCV Phase 3 clinical trial
+5 more records
Product overview1 text field

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on small molecule drug discovery and development for viral infections and immunological diseases. The company's product portfolio includes marketed hepatitis C virus treatments (glecaprevir/MAVYRET and paritaprevir/VIEKIRA PAK, commercialized by AbbVie), clinical-stage RSV antivirals (zelicapavir and EDP-323 with Fast Track designation), COVID-19 treatment candidate (EDP-235), and an expanding immunology pipeline targeting type 2 inflammatory diseases including KIT inhibitor EDP-978 (Phase 1 for chronic urticaria), STAT6 inhibitor EPS-3903 (preclinical for atopic dermatitis), and MRGPRX2 inhibitors (discovery stage). The company also has a hepatitis B virus candidate (EDP-514, Fast Track designated) in clinical development.

Product and service9 records
1Glecaprevir (MAVYRET/MAVIRET)
CategoryMarketed Antiviral Product
Description

Protease inhibitor co-formulated with pibrentasvir as AbbVie's direct-acting antiviral combination treatment for hepatitis C virus, discovered by Enanta and commercialized by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.). The only 8-week cure for HCV, approved for both acute and chronic HCV.

2Paritaprevir (VIEKIRA PAK)
CategoryMarketed Antiviral Product
Description

Protease inhibitor developed through Enanta's collaboration with AbbVie, included in fixed-dose combinations with other direct-acting antivirals for treatment of selected HCV genotypes, commercialized by AbbVie as VIEKIRA PAK (U.S.) and VIEKIRAX (ex-U.S.).

3Zelicapavir (EDP-938)
CategoryClinical-Stage Antiviral Product
Description

Oral N-protein inhibitor for respiratory syncytial virus (RSV) treatment, dosed in more than 700 people with favorable safety profile. Phase 2b/3 registrational trial for high-risk adults planned. Has FDA Fast Track designation.

4EDP-323
CategoryClinical-Stage Antiviral Product
Description

Oral L-protein inhibitor targeting RSV polymerase for treatment of respiratory syncytial virus with sub-nanomolar potency in vitro. Has FDA Fast Track designation. Completed Phase 2a challenge study showing statistically significant reductions in viral load and symptoms.

5EDP-235
CategoryClinical-Stage Antiviral Product
Description

Oral 3CL protease inhibitor (3CLpro) for treatment of COVID-19 with nanomolar activity against all SARS-CoV-2 variants and potent antiviral activity against other human coronaviruses. Has FDA Fast Track designation. Completed Phase 2 SPRINT study.

6EDP-514
CategoryClinical-Stage Antiviral Product
Description

Novel core inhibitor (capsid assembly modulator) for hepatitis B virus (HBV) treatment that disrupts assembly and replication of HBV at multiple steps in viral life cycle. Has FDA Fast Track designation. Phase 1 studies completed with robust antiviral activity.

7EDP-978
CategoryClinical-Stage Immunology Product
Description

Oral once-daily KIT inhibitor for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases with potent nanomolar activity. Phase 1 trial initiated with topline data expected Q4 2026.

8EPS-3903
CategoryPreclinical Immunology Product
Description

Selective oral STAT6 inhibitor for atopic dermatitis and other Th2 inflammatory diseases with nanomolar potency and high selectivity over other STATs. Offers potential as 'oral dupilumab' by directly blocking IL-4/IL-13 signaling. IND-enabling activities ongoing.

9MRGPRX2 Inhibitors
CategoryDiscovery-Stage Immunology Product
Description

Oral inhibitors targeting MRGPRX2 receptor expressed on mast cells for chronic spontaneous urticaria and atopic dermatitis with nanomolar potency in cellular assays. Multiple compounds in preclinical evaluation.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Penta Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-18
Description

Collaboration for a Phase 2b pediatric clinical trial of zelicapavir in RSV patients aged 28 days to 36 months, with topline data expected in 2027. The Penta Foundation is a well-established pediatric research network.

stocktitan.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-18
Description

Collaboration for Phase 2b pediatric RSV trial in Thailand as part of Enanta's global pediatric development program for zelicapavir, with data expected in 2027.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2012-02-01
Description

In February 2012, Enanta entered into an exclusive collaboration and license agreement with Novartis for worldwide development, manufacture and commercialization of its lead development candidate EDP-239 from its NS5A HCV inhibitor program.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2006-11-01
Description

In November 2006, Enanta entered into a Collaborative Development and License Agreement with Abbott (later AbbVie) to identify, develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. This partnership led to FDA approval of VIEKIRA PAK (2014) and MAVYRET (2017), which have cured over one million patients globally. AbbVie is responsible for all worldwide marketing and sales, with Enanta receiving ongoing royalty payments.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2004-07-01
Description

In July 2004, Enanta entered into an agreement with Shionogi to develop and commercialize an antibiotic (EDP-420) for the treatment of community-acquired pneumonia and community respiratory tract infections.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Assembly Biosciences is a clinical-stage biotechnology company developing small molecule therapies for chronic hepatitis B virus infection, including core inhibitors and other mechanisms that directly overlap with Enanta's EDP-514 HBV core inhibitor program.

TypeDirect peer
Description

Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B and other liver diseases, with capsid inhibitors and other small molecule candidates that directly compete with Enanta's EDP-514 in the HBV space.

TypeEmerging player
Description

Brii Biosciences is a clinical-stage biopharmaceutical company developing therapeutics for infectious diseases and central nervous system disorders, with a portfolio that includes HBV functional cure programs. The company has partial overlap with Enanta in HBV and broader infectious disease focus.

TypeDirect peer
Description

Vir Biotechnology is a clinical-stage immunology company developing antiviral therapies for serious infectious diseases, including RSV, hepatitis B, and influenza. Vir's broad antiviral pipeline and focus on small molecule and antibody approaches for respiratory viruses makes it a direct competitor to Enanta's RSV and HBV programs.

TypeOthers
Description

AbbVie is Enanta's most important commercial partner and the global marketer of MAVYRET/MAVIRET and VIEKIRA PAK containing Enanta's discovered protease inhibitors. While not a direct competitive peer, AbbVie is the ecosystem participant that has commercialized Enanta's discoveries and continues to pay royalties, making the relationship economically defining for Enanta.

TypeDirect peer
Description

Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics for norovirus, influenza, COVID-19, and hepatitis B using structure-based drug design. The company shares Enanta's small molecule approach to viral diseases, including direct overlap in HBV and coronaviruses.

TypeDirect peer
Description

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing small molecule oral therapies for chronic Hepatitis B virus infection. Like Enanta, it targets HBV with novel mechanisms (capsid inhibitors, RNAi), competing for the same patient population with similar small-molecule chemistry approaches.

TypeBroad incumbent
Description

Gilead Sciences is the dominant global player in HIV and HCV treatment (with HCV franchises including Harvoni, Sovaldi, Epclusa) and also develops antivirals in HBV and respiratory viruses. As the established incumbent in the antiviral space that Enanta helped advance through AbbVie's MAVYRET, Gilead represents the competitive benchmark for hepatitis antivirals.

TypeDirect peer
Description

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral antiviral therapeutics, notably for COVID-19 (3CL protease inhibitors similar to Enanta's EDP-235) and hepatitis C. Atea's direct overlap in 3CL protease chemistry and HCV development makes it a highly relevant peer.

TypeDirect peer
Description

Eiger BioPharmaceuticals developed small molecule therapies for hepatitis B and hepatitis D viruses, including lonafarnib for HDV. As a small-cap antiviral company targeting hepatitis with oral therapies, Eiger has been a direct peer to Enanta in the HBV/HDV space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enanta Pharmaceuticals

Biopharmaceuticalsenanta.com

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunology, generating royalty revenue from AbbVie's hepatitis C treatments while advancing a pipeline in RSV, HBV, and inflammatory diseases.

What Enanta Pharmaceuticals does

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunological diseases. Founded in 1995 and headquartered in Watertown, Massachusetts, the company operates with fewer than 200 employees and trades on NASDAQ under ticker ENTA. Enanta's research is anchored in medicinal chemistry and has historically focused on protease inhibitors, exemplified by the discovery of glecaprevir and paritaprevir — compounds commercialized by AbbVie in the HCV regimens MAVYRET/MAVIRET and VIEKIRA PAK, which have collectively cured more than one million patients.

The company's clinical pipeline spans multiple mechanisms of action: RSV antivirals (zelicapavir, an N-protein inhibitor advancing to registrational Phase 2b/3; and EDP-323, an L-protein inhibitor with Phase 2a data), a COVID-19 candidate (EDP-235, a 3CL protease inhibitor), an HBV core inhibitor (EDP-514), and an expanding immunology franchise (EDP-978, an oral KIT inhibitor in Phase 1; EPS-3903, a STAT6 inhibitor in IND-enabling studies; and MRGPRX2 inhibitors in discovery). Four candidates hold FDA Fast Track designation, supporting expedited development pathways.

Enanta's business model is dual-track. Revenue is generated almost entirely through royalty payments from AbbVie on worldwide sales of MAVYRET/MAVIRET — approximately $18.6 million in Q1 FY2026 — providing a cash-generative base that has historically delivered over $1 billion in non-dilutive financing through the AbbVie collaboration. The company is advancing pipeline assets toward registrational milestones with the intent of securing new commercialization partnerships or building independent sales capability for future launches. An October 2025 upsized public offering raised $74.75 million, extending the cash position to $241.9 million as of December 31, 2025 and funding operations into fiscal 2029. The company also retains optionality on pipeline assets via a dedicated business development function and historical collaborations with Novartis, Shionogi, and government funders.

Enanta Pharmaceuticals firmographics

Firmographics
Name
Enanta Pharmaceuticals
Legal name
Enanta Pharmaceuticals, Inc.
Website
https://enanta.com
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
101–250 employees
Short description
Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunology, generating royalty revenue from AbbVie's hepatitis C treatments while advancing a pipeline in RSV, HBV, and inflammatory diseases.
Ownership category
akta.pro rank

Enanta Pharmaceuticals industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Small molecule drug discovery
  • Antiviral therapeutics
  • Hepatitis C treatment
  • RSV drug development
  • Immunology drug development

Where Enanta Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Enanta Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Royalty Payments from AbbVie: Enanta receives ongoing royalty payments from AbbVie based on sales of MAVYRET/MAVIRET (glecaprevir/pibrentasvir) for hepatitis C treatment. Revenue was $18.6 million in fiscal Q1 2026 (quarter ended December 31, 2025), up from $17.0 million in the prior year period.
  2. Public Stock Offering: Enanta raised approximately $74.75 million through an upsized public offering of 7,475,000 shares of common stock at $10.00 per share in October 2025 to fund clinical trials, research, and development, and general corporate purposes.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Enanta Pharmaceuticals product offering

Product offering

Core offering

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers, develops, and commercializes small molecule drugs for viral infections (HCV, RSV, HBV, COVID-19) and immunological diseases. Its marketed products (glecaprevir and paritaprevir, used in AbbVie's MAVYRET/MAVIRET and VIEKIRA PAK regimens for hepatitis C) are commercialized by AbbVie under a longstanding collaboration that has cured over one million patients. The company's clinical pipeline includes zelicapavir and EDP-323 for RSV, EDP-235 for COVID-19, EDP-514 for HBV, and EDP-978, EPS-3903, and MRGPRX2 inhibitors for immunology indications.

Product overview

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on small molecule drug discovery and development for viral infections and immunological diseases. The company's product portfolio includes marketed hepatitis C virus treatments (glecaprevir/MAVYRET and paritaprevir/VIEKIRA PAK, commercialized by AbbVie), clinical-stage RSV antivirals (zelicapavir and EDP-323 with Fast Track designation), COVID-19 treatment candidate (EDP-235), and an expanding immunology pipeline targeting type 2 inflammatory diseases including KIT inhibitor EDP-978 (Phase 1 for chronic urticaria), STAT6 inhibitor EPS-3903 (preclinical for atopic dermatitis), and MRGPRX2 inhibitors (discovery stage). The company also has a hepatitis B virus candidate (EDP-514, Fast Track designated) in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Glecaprevir (MAVYRET/MAVIRET) Protease inhibitor co-formulated with pibrentasvir as AbbVie's direct-acting antiviral combination treatment for hepatitis C virus, discovered by Enanta and commercialized by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.). The only 8-week cure for HCV, approved for both acute and chronic HCV.
  • Paritaprevir (VIEKIRA PAK) Protease inhibitor developed through Enanta's collaboration with AbbVie, included in fixed-dose combinations with other direct-acting antivirals for treatment of selected HCV genotypes, commercialized by AbbVie as VIEKIRA PAK (U.S.) and VIEKIRAX (ex-U.S.).
  • Zelicapavir (EDP-938) Oral N-protein inhibitor for respiratory syncytial virus (RSV) treatment, dosed in more than 700 people with favorable safety profile. Phase 2b/3 registrational trial for high-risk adults planned. Has FDA Fast Track designation.
  • EDP-323 Oral L-protein inhibitor targeting RSV polymerase for treatment of respiratory syncytial virus with sub-nanomolar potency in vitro. Has FDA Fast Track designation. Completed Phase 2a challenge study showing statistically significant reductions in viral load and symptoms.
  • EDP-235 Oral 3CL protease inhibitor (3CLpro) for treatment of COVID-19 with nanomolar activity against all SARS-CoV-2 variants and potent antiviral activity against other human coronaviruses. Has FDA Fast Track designation. Completed Phase 2 SPRINT study.
  • EDP-514 Novel core inhibitor (capsid assembly modulator) for hepatitis B virus (HBV) treatment that disrupts assembly and replication of HBV at multiple steps in viral life cycle. Has FDA Fast Track designation. Phase 1 studies completed with robust antiviral activity.
  • EDP-978 Oral once-daily KIT inhibitor for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases with potent nanomolar activity. Phase 1 trial initiated with topline data expected Q4 2026.
  • EPS-3903 Selective oral STAT6 inhibitor for atopic dermatitis and other Th2 inflammatory diseases with nanomolar potency and high selectivity over other STATs. Offers potential as 'oral dupilumab' by directly blocking IL-4/IL-13 signaling. IND-enabling activities ongoing.
  • MRGPRX2 Inhibitors Oral inhibitors targeting MRGPRX2 receptor expressed on mast cells for chronic spontaneous urticaria and atopic dermatitis with nanomolar potency in cellular assays. Multiple compounds in preclinical evaluation.

Quantifiable outcome

  • 96.2% sustained virological response rate at 12 weeks (SVR12) for MAVIRET in acute HCV Phase 3 clinical trial
  • +5 more outcomes

Companies that use Enanta Pharmaceuticals

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Enanta Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Enanta Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, minor and flagship.

  • Penta FoundationcoreStrategic or Co-development Partner · 18 June 2026Collaboration for a Phase 2b pediatric clinical trial of zelicapavir in RSV patients aged 28 days to 36 months, with topline data expected in 2027. The Penta Foundation is a well-established pediatric research network.
  • Chiang Mai University's AMS-PHPT Research UnitcoreStrategic or Co-development Partner · 18 June 2026Collaboration for Phase 2b pediatric RSV trial in Thailand as part of Enanta's global pediatric development program for zelicapavir, with data expected in 2027.
  • NovartisminorStrategic or Co-development Partner · 1 February 2012In February 2012, Enanta entered into an exclusive collaboration and license agreement with Novartis for worldwide development, manufacture and commercialization of its lead development candidate EDP-239 from its NS5A HCV inhibitor program.
  • AbbVieflagshipStrategic or Co-development Partner · 1 November 2006In November 2006, Enanta entered into a Collaborative Development and License Agreement with Abbott (later AbbVie) to identify, develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. This partnership led to FDA approval of VIEKIRA PAK (2014) and MAVYRET (2017), which have cured over one million patients globally. AbbVie is responsible for all worldwide marketing and sales, with Enanta receiving ongoing royalty payments.
  • ShionogiminorStrategic or Co-development Partner · 1 July 2004In July 2004, Enanta entered into an agreement with Shionogi to develop and commercialize an antibiotic (EDP-420) for the treatment of community-acquired pneumonia and community respiratory tract infections.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Enanta Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Assembly Biosciences: Assembly Biosciences is a clinical-stage biotechnology company developing small molecule therapies for chronic hepatitis B virus infection, including core inhibitors and other mechanisms that directly overlap with Enanta's EDP-514 HBV core inhibitor program.
  • Aligos Therapeutics: Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B and other liver diseases, with capsid inhibitors and other small molecule candidates that directly compete with Enanta's EDP-514 in the HBV space.
  • Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing antiviral therapies for serious infectious diseases, including RSV, hepatitis B, and influenza. Vir's broad antiviral pipeline and focus on small molecule and antibody approaches for respiratory viruses makes it a direct competitor to Enanta's RSV and HBV programs.
  • Cocrystal Pharma: Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics for norovirus, influenza, COVID-19, and hepatitis B using structure-based drug design. The company shares Enanta's small molecule approach to viral diseases, including direct overlap in HBV and coronaviruses.
  • Arbutus Biopharma: Arbutus Biopharma is a clinical-stage biopharmaceutical company developing small molecule oral therapies for chronic Hepatitis B virus infection. Like Enanta, it targets HBV with novel mechanisms (capsid inhibitors, RNAi), competing for the same patient population with similar small-molecule chemistry approaches.
  • Atea Pharmaceuticals: Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral antiviral therapeutics, notably for COVID-19 (3CL protease inhibitors similar to Enanta's EDP-235) and hepatitis C. Atea's direct overlap in 3CL protease chemistry and HCV development makes it a highly relevant peer.
  • Eiger BioPharmaceuticals: Eiger BioPharmaceuticals developed small molecule therapies for hepatitis B and hepatitis D viruses, including lonafarnib for HDV. As a small-cap antiviral company targeting hepatitis with oral therapies, Eiger has been a direct peer to Enanta in the HBV/HDV space.

Emerging players

  • Brii Biosciences: Brii Biosciences is a clinical-stage biopharmaceutical company developing therapeutics for infectious diseases and central nervous system disorders, with a portfolio that includes HBV functional cure programs. The company has partial overlap with Enanta in HBV and broader infectious disease focus.

Others

  • AbbVie: AbbVie is Enanta's most important commercial partner and the global marketer of MAVYRET/MAVIRET and VIEKIRA PAK containing Enanta's discovered protease inhibitors. While not a direct competitive peer, AbbVie is the ecosystem participant that has commercialized Enanta's discoveries and continues to pay royalties, making the relationship economically defining for Enanta.

Broad incumbents

  • Gilead Sciences: Gilead Sciences is the dominant global player in HIV and HCV treatment (with HCV franchises including Harvoni, Sovaldi, Epclusa) and also develops antivirals in HBV and respiratory viruses. As the established incumbent in the antiviral space that Enanta helped advance through AbbVie's MAVYRET, Gilead represents the competitive benchmark for hepatitis antivirals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Enanta Pharmaceuticals social profiles

Digital presence

Enanta Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enanta Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

Enanta Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enanta Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enanta Pharmaceuticals

What does Enanta Pharmaceuticals do?

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers, develops, and commercializes small molecule drugs for viral infections (HCV, RSV, HBV, COVID-19) and immunological diseases. Its marketed products (glecaprevir and paritaprevir, used in AbbVie's MAVYRET/MAVIRET and VIEKIRA PAK regimens for hepatitis C) are commercialized by AbbVie under a longstanding collaboration that has cured over one million patients. The company's clinical pipeline includes zelicapavir and EDP-323 for RSV, EDP-235 for COVID-19, EDP-514 for HBV, and EDP-978, EPS-3903, and MRGPRX2 inhibitors for immunology indications.

Is Enanta Pharmaceuticals a public or private company?

Enanta Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Enanta Pharmaceuticals founded?

Enanta Pharmaceuticals was founded in 1995. It employs 101 to 250 people.

Where is Enanta Pharmaceuticals based?

Enanta Pharmaceuticals is headquartered in Watertown, United States, in the North America region.

How does Enanta Pharmaceuticals make money?

Two revenue lines are on record. Royalty Payments from AbbVie is the primary driver. The others are public Stock Offering.

Who are Enanta Pharmaceuticals's main competitors?

Direct peers on record are Assembly Biosciences, Aligos Therapeutics, Vir Biotechnology, Cocrystal Pharma, Arbutus Biopharma, Atea Pharmaceuticals and Eiger BioPharmaceuticals. Brii Biosciences is listed as an emerging player. AbbVie is listed as an others. Gilead Sciences is listed as a broad incumbent.

Does Enanta Pharmaceuticals have an API?

No public API is recorded for Enanta Pharmaceuticals.

What industry is Enanta Pharmaceuticals in?

Enanta Pharmaceuticals's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEnanta Pharmaceuticals at Jefferies conference: pipeline grows, costs cutEnanta Pharmaceuticals outlined its RSV and immunology pipeline at the Jefferies conference, including RSV dosing and KIT inhibitor readouts in Q1 2025. The company cut about one-third of its workforce to preserve capital, and CEO Jay Luly will retire on February 1, 2025.TradingViewEnanta Pharmaceuticals FY 2026: Revenue $63M, EPS ($2.35) — 10-K SummaryEnanta Pharmaceuticals reported FY2026 revenue of $63M, down 3.6% year over year, with a net loss of $68.25M, narrowing 16.7% from the prior year. The company dosed the first patient in its RSV RESOLVE trial in October and expects topline data in 2027. Its cash position of $194.5M is expected to fund operations through fiscal 2029.ChartmillEnanta Pharmaceuticals (NASDAQ:ENTA) Posts Revenue Miss and In-Line EPS as Shares Slip After HoursEnanta Pharmaceuticals reported fiscal Q4 revenue of $12.9 million, missing the $14.5 million consensus, while its per-share loss of $0.81 was in line with the $0.799 consensus. The stock fell about 3.9% after hours, driven by the revenue shortfall and reliance on declining AbbVie HCV royalties. Management expects cash to fund operations into fiscal 2029.Quiver QuantitativeENANTA PHARMACEUTICALS ($ENTA) Releases Q4 2026 Earnings, Stock Rises | ENTA Stock NewsENANTA Pharmaceuticals reported Q4 2026 earnings of -$0.81 per share, missing estimates by $0.01, and revenue of $12.87 million, down $1.61 million from estimates. The stock rose 2.5% after market close. Analysts have issued one buy rating.YahooEnanta Pharmaceuticals: Fiscal Q4 Earnings SnapshotEnanta Pharmaceuticals reported a fiscal Q4 loss of $23.7 million, or 81 cents per share, with revenue of $12.9 million. The company's full-year loss was $68.2 million, or $2.35 per share, on revenue of $63 million.TradingViewEnanta Pharmaceuticals (ENTA) Reports FY2026 Net Loss of $68.2MEnanta Pharmaceuticals reported FY2026 net loss of $68.2M, down from $81.9M in FY2025, with revenue of $63.0M versus $65.3M. Cash and marketable securities totaled $194.5M, and the company expects funding into fiscal 2029. Planned LOTUS topline data is expected in Q1 2027.MarketWatchEnanta Pharmaceuticals President, CEO Jay Luly to RetireEnanta Pharmaceuticals announced that President and CEO Jay Luly will retire on Feb. 1, 2027, after more than two decades at the company. The board launched a search for a successor, considering internal and external candidates, and named Tara Kieffer chief operating officer. Luly will serve as adviser through 2027.YahooFirst patient dosed in Enanta’s Phase IIb/III trial for RSVEnanta Pharmaceuticals dosed the first patient in its global Phase IIb/III RESOLVE trial for zelicapavir in high-risk adult RSV patients. The trial assesses safety and efficacy, with Phase IIb results expected in 2027. Zelicapavir holds fast track designation and has been tested in over 700 individuals.Ticker ReportComparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)Amphastar Pharmaceuticals beats Enanta Pharmaceuticals on 8 of 14 factors, including profitability and revenue. Enanta has a higher consensus rating and potential upside, while Amphastar trades at a lower price-to-earnings ratio. Analysts favor Enanta despite Amphastar's stronger financials.American Banking and Market NewsCritical Survey: Enanta Pharmaceuticals (NASDAQ:ENTA) & Scilex (NASDAQ:SCLX)Enanta Pharmaceuticals beats Scilex on 11 of 14 factors, including higher revenue, lower P/E, and stronger analyst consensus. Enanta's consensus price target is $19.00, implying 54.47% upside, while Scilex has a sell rating and negative net margin.